Current modalities and new advances in the treatment of basal cell carcinoma

International Journal of Dermatology

Volumn 45, Issue 5, 2006, Pages 489-498

  Ceilley, Roger I ^a,b   Del Rosso, James Q ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; FLUOROURACIL; IMIQUIMOD;

APPLICATION SITE BURNING; APPLICATION SITE INFLAMMATION; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE SCABBING; APPLICATION SITE SCAR; APPLICATION SITE SWELLING; BASAL CELL CARCINOMA; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; CRYOSURGERY; CURETTAGE; ERYTHEMA; ESTHETICS; HIGH RISK POPULATION; HUMAN; HYPERPIGMENTATION; INTERMETHOD COMPARISON; PHOTODYNAMIC THERAPY; PRURITUS; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; SKIN MANIFESTATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CRYOSURGERY; CURETTAGE; ELECTROSURGERY; HUMANS; MOHS SURGERY; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS;

EID: 33646167641     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.02673.x     Document Type: Review

References (58)

1. Mikkilineni R, Weinstock MA. Epidemiology of skin cancer. In: Atlas of Clinical Oncology: Skin Cancer. London, UK: BC Decker, Inc., 2001: 1-15.
2. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 2002; 147: 41-47.
3. Hoban PR, Ramachandran S, Strange RC. Environment, phenotype and genetics: Risk factors associated with BCC of the skin. Expert Rev Anticancer Ther 2002; 2: 570-579.
4. Carroll RP, Ramsay HM, Fryer AA, et al. Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: A prospective study in Queensland, Australia. Am J Kidney Dis 2003; 41: 676-683.
5. Hartevelt MM, Bavinck JN, Kootte AM, et al. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990; 49: 506-509.
6. Leffell DJ, Carucci JA. Management of skin cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, Vol. 2, 6th edn. Philadelphia, PA: Lippincott. Williams & Wilkins, 2001: 1976-2002.
7. Basal cell and squamous cell skin cancers. Clinical practice guidelines in oncology. J Natl Comp Cancer Network 2004; 2: 6-27.
8. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135: 1177-1183.
9. Dellon AL, DeSilva S, Connolly M, et al. Prediction of recurrence in incompletely excised basal cell carcinoma. Plast Reconstr Surg 1985; 75: 860-871.
10. Gooding CA, White G, Yatsuhashi M. Significance of marginal extension in excised basal-cell carcinoma. N Engl J Med 1965; 273: 923-924.
11. Griffiths RW. Audit of histologically incompletely excised basal cell carcinomas: Recommendations for management by re-excision. Br J Plast Surg 1999; 52: 24-28.
12. Nagore E, Grau C, Molinero J, et al. Positive margins in basal cell carcinoma: Relationship to clinical features and recurrence risk. A retrospective study of 248 patients. J Eur Acad Dermatol Venereol 2003; 17: 167-170.
13. Pascal RR, Hobby LW, Lattes R, et al. Prognosis of "incompletely excised" versus "completely excised" basal cell carcinoma. Plast Reconstr Surg 1968; 41: 328-332.
14. Richmond JD, Davie RM. The significance of incomplete excision in patients with basal cell carcinoma. Br J Plast Surg 1987; 40: 63-67.
15. Kopf AW, Bart RS, Schrager D, et al. Curettage-electrodesiccation treatment of basal cell carcinomas. Arch Dermatol 1977; 113: 439-443.
16. Silverman MK, Kopf AW, Grin CM et al. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol 1991; 17: 720-726.
17. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: Implications for patient follow-up. J Dermatol Surg Oncol 1989; 15: 315-328.
18. Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989; 15: 424-431.
19. Jiang SB. Mohs surgery [eMedicine Web site]. Available at: http://www.emedicine.com/ent/topic29.htm. Accessed November 30, 2004.
20. Wennberg AM, Larko O, Stenquist B. Five-year results of Mohs' micrographic surgery for aggressive facial basal cell carcinoma in Sweden. Acta Derm Venereol 1999; 79: 370-372.
21. Silverman MK, Kopf AW, Gladstein AH, et al. Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. J Dermatol Surg Oncol. 1992; 18: 549-554.
22. Fink-Puches R, Soyer HP, Hofer A, et al. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Arch Dermatol 1998; 134: 821-826.
23. Soler AM, Warloe T, Berner A, et al. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 2001; 145: 467-471.
24. Basset-Seguin N, Ibbotson S, Emtestam L. Photodynamic therapy using Metvix™ is as efficacious as cryotherapy in BCC with better cosmetic results. J Eur Acad Dermatol Venereol 15, 226. Cited by: Foley P. Clinical efficacy of methylaminolevulinate (metvix) photodynamic therapy. J Dermatolog Treat 2003; 14 (Suppl. 3): 15-22. 2001.
25. Haller JC, Cairnduff F, Slack G, et al. Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy. Br J Dermatol 2000; 143: 1270-1275.
26. Kumar P, Orton CI, McWilliam LJ, et al. Incidence of incomplete excision in surgically treated basal cell carcinoma: A retrospective clinical audit. Br J Plast Surg 2000; 53: 563-566.
27. Bogdanov-Berezovsky A, Cohen A, Glesinger R, et al. Clinical and pathological findings in reexcision of incompletely excised basal cell carcinomas. Ann Plast Surg 2001; 47: 299-302.
28. Dieu T, Macleod AM. Incomplete excision of basal cell carcinomas: A retrospective audit. ANZ J Surg 2002; 72: 219-221.
29. Chiller K, Passaro D, McCalmont T, et al. Efficacy of curettage before excision in clearing surgical margins of nonmelanoma skin cancer. Arch Dermatol 2000; 136: 1327-1332.
30. Salasche SJ. Status of curettage and desiccation in the treatment of primary basal cell carcinoma. J Am Acad Dermatol 1984; 10: 285-287.
31. Werlinger KD, Upton G, Moore AY. Recurrence rates of primary nonmelanoma skin cancers treated by surgical excision compared to electrodesiccation-curettage in a private dermatological practice. Dermatol Surg 2002; 28: 1138-1142; discussion 1142.
32. Robins P, Albom MJ. Recurrent basal cell carcinomas in young women. J Dermatol Surg 1975; 1: 49-51.
33. Hruza GJ. Mohs micrographic surgery local recurrences. J Dermatol Surg Oncol 1994; 20: 573-577.
34. Cook JL, Perone JB. A prospective evaluation of the incidence of complications associated with Mohs micrographic surgery. Arch Dermatol 2003; 139: 143-152.
35. Liede KE, Haukka JK, Saxen LM, et al. Increased tendency towards gingival bleeding caused by joint effect of alpha-tocopherol supplementation and acetylsalicylic acid. Ann Med 1998; 30: 542-546.
36. Pribitkin ED, Boger G. Herbal therapy: What every facial plastic surgeon must know. Arch Facial Plast Surg 2001; 3: 127-132.
37. Cook J, Zitelli JA. Mohs micrographic surgery: A cost analysis. J Am Acad Dermatol 1998; 39: 698-703.
38. Mallon E, Dawber R. Cryosurgery in the treatment of basal cell carcinoma. Assessment of one and two freeze-thaw cycle schedules. Dermatol Surg 1996; 22: 854-858.
39. Kuflik EG, Gage AA. Recurrent basal cell carcinoma treated with cryosurgery. J Am Acad Dermatol 1997; 37: 82-84.
40. Kuflik EG, Cage AA. Cryosurgical Treatment for Skin Cancer. New York: Igaku-Shoin, 1990: 243-254.
41. Zouboulis CC. Cryosurgery in dermatology. Eur J Dermatol 1998; 8: 466-474.
42. Thissen MR, Nieman FH, Ideler AH, et al. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg 2000; 26: 759-764.
43. Martin H, Strong E, Spiro RH. Radiation-induced skin cancer of the head and neck. Cancer 1970; 25: 61-71.
44. Wang I, Bendsoe N, Klinteberg CA et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: Results of a phase III clinical trial. Br J Dermatol 2001; 144: 832-840.
45. Rhodes LE, de Rie M, Enstrom Y et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140: 17-23.
46. LEVULAN®KERASTICK™ (aminolevulinic acid HCI) for topical solution, 20% (Package Insert). Wilmington, MA: DUSA Pharmaceuticals, Inc, 1999.
47. EFUDEX® (fluorouracil) topical solutions and cream (product pamphlet). Costa Mesa, CA: ICN Pharmaceuticals, Inc, 2000.
48. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-813.
49. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-398.
50. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002; 138: 1165-1171.
51. Epstein E. Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol 1985; 121: 207-213.
52. Tsuji T, Otake N, Nishimura M. Cryosurgery and topical fluorouracil: A treatment method for widespread basal cell epithelioma in basal cell nevus syndrome. J Dermatol 1993; 20: 507-513.
53. Stanley MA. Imiquimod and the imidazoquinolones. mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27: 571-577.
54. Berman B, Sullivan T, De Araujo T, et al. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003; 149 (Suppl. 66): 59-61.
55. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-733.
56. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147: 1227-1236.
57. Huber A, Huber JD, Skinner RB Jr., et al. Topical imiquimod treatment for nodular basal cell carcinomas: An open-label series. Dermatol Surg 2004; 30: 429-430.
58. Torres A, Niemeyer A, Berkes B, et al. Treatment of basal cell carcinoma using imiquimod 5% cream as an adjuvant therapy to Mohs micrographic surgery. J Eur Acad Dermatol Venereol 2003; 17 (Suppl. 3).